A sulindac analogue is effective against XXXX in @entity19 .

@entity32 @entity455 @entity19 @entity5 @entity10521 @entity3483 @entity420
OBJECTIVES: To examine whether a @entity10521 derivative (C-18) with previously reported anti-angiogenic properties limits @entity3483 ( @entity3483 ) formation in @entity19 . METHODS: @entity3483 was generated by intrapleural injection of @entity19 @entity420 cells in C57BL/6 @entity19 . Animals were divided into three groups, a control group and two treatment groups receiving intraperitoneally a daily dose of either 1 mg or 2 mg of C-18 for a total of 12 doses. @entity19 were sacrificed on day 14. MEASUREMENTS AND MAIN RESULTS: Pleural fluid volume and the number of @entity5 implantations were measured. @entity5 angiogenesis, @entity455 and the host @entity32 response were also assessed. C-18 significantly limited pleural fluid formation and inhibited @entity5 . The mean  SEM pleural fluid volume was 758  63  l for the control group, compared to 492  120  l (p=0.042) and 279  77  l (p<0.001) for the low dose and high dose group of C-18, respectively. Control group animals had 6.2  1 @entity5 , while C-18 treated animals had 3.1  0.8 (p=0.014) and 3  0.7 (p=0.009) for the low and high dose respectively. In addition C-18 significantly suppressed @entity455 . No significant difference in @entity5 angiogenesis and @entity32 response was observed, while there was also no measurable effect in @entity5 cell apoptosis and proliferation in vitro and in vivo. CONCLUSIONS: C-18 halted experimental @entity3483 formation and @entity5 , through down-regulation of @entity455 .
